Movement Disorders (revue) - Analysis (France)

Index « Auteurs » - entrée « Robert A. Hauser »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Rivka Inzelberg < Robert A. Hauser < Robert E. Gross  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 9.
Ident.Authors (with country if any)Title
000087 (2013) Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destée [France] ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe [Autriche] ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia TrenkwalderAFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
000157 (2011) Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas]Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
000190 (2010) Carlo Colosimo [Italie] ; Pablo Martínez-Martín [Espagne] ; Giovanni Fabbrini [Italie] ; Robert A. Hauser [États-Unis] ; Marcelo Merello [Argentine] ; Janis Miyasaki [Canada] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] ; Christopher G. Goetz [États-Unis]Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations
000200 (2010) Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche]Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease
000217 (2010) Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France]Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease
000219 (2010) Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas]Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
000308 (2008) C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France]A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
000314 (2007) Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
000322 (2007) Robert A. Hauser [États-Unis] ; Laurence Salin [France] ; Nolwenn Juhel [France] ; Victor L. Konyago [États-Unis]Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

List of associated KwdEn.i

Nombre de
documents
Descripteur
9Humans
8Aged
8Double-Blind Method
8Female
8Male
8Middle Aged
8Nervous system diseases
8Parkinson Disease (drug therapy)
8Parkinson disease
8Parkinson's disease
6Dose-Response Relationship, Drug
6Severity of Illness Index
5Treatment Outcome
4Antiparkinson Agents (adverse effects)
4Dopamine agonist
4Treatment
3Antiparkinson Agents (therapeutic use)
3Drug Administration Schedule
3Follow-Up Studies
3Time Factors
3dopamine agonist
3treatment
2Antiparkinson Agents (administration & dosage)
2Benzothiazoles (administration & dosage)
2Benzothiazoles (adverse effects)
2Benzoxazoles (therapeutic use)
2Clinical trial
2Delayed-Action Preparations (therapeutic use)
2Disability Evaluation
2Dyskinesia
2Dyskinesia, Drug-Induced (etiology)
2Indoles (therapeutic use)
2Levodopa (adverse effects)
2Levodopa (therapeutic use)
2Pardoprunox
2Partial agonist
2Piperazines (therapeutic use)
2Pramipexole
2Release
2Retrospective Studies
2dyskinesia
2monotherapy
2partial dopamine agonist
1Adult
1Aged, 80 and over
1Amantadine (adverse effects)
1Amantadine (therapeutic use)
1Antiparasitic Agents (therapeutic use)
1Benzothiazoles (therapeutic use)
1Bicyclo Compounds, Heterocyclic (therapeutic use)
1Cognition Disorders (drug therapy)
1Cognition Disorders (etiology)
1Complication
1Confidence Intervals
1Delayed-Action Preparations (administration & dosage)
1Delayed-Action Preparations (adverse effects)
1Disease Progression
1Dopamine
1Dopamine Agonists (therapeutic use)
1Double blind study
1Dyskinesia, Drug-Induced (diagnosis)
1Dyskinesia, Drug-Induced (drug therapy)
1Evaluation
1Evaluation Studies as Topic
1Force
1Human
1Indans (therapeutic use)
1Indoles (adverse effects)
1International Cooperation
1Levodopa
1Modification
1NS 2330
1Neuroprotective Agents (therapeutic use)
1Neurotransmitter Uptake Inhibitors (therapeutic use)
1Outcome Assessment (Health Care)
1Parkinson Disease (complications)
1Parkinson Disease (physiopathology)
1Parkinsonian Disorders (drug therapy)
1Patient Satisfaction
1Placebo
1Psychiatric Status Rating Scales
1Psychometrics
1Quality of Life
1Questionnaires
1Rasagiline
1Recommendation
1Reliability
1Reproducibility of Results
1Reuptake inhibitor
1Ropinirole
1Safety
1Tesofensine
1Validity
1clinical trial
1clinimetrics
1delayed start design
1disease modification
1dopamine reuptake inhibitor
1dopamine transporter
1levodopa

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Robert A. Hauser" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Robert A. Hauser" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Robert A. Hauser
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024